FOR IMMEDIATE RELEASE

October 5th, 2022

Anwita Biosciences, Inc. Announces Multiple Poster Presentations Showcasing Its Three Cytokine-Based Therapeutics at 37th Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

SAN CARLOS, California, October 5th, 2022 – Anwita Biosciences, Inc. (“Anwita”), a clinical-stage innovative biopharmaceutical company developing proprietary optimized cytokine-based therapeutics for cancer patients, today announced three poster presentations at the upcoming SITC 2022 Annual Meeting to be held from November 10-12, 2022, in Boston, MA.

“Over the past year, we have made tremendous progress on multiple fronts, including dosing of first patient in our Exenokine-21 (JS014) Phase 1 trial, and advancing several cytokine assets into late-stage preclinical development or into IND-enabling phase” said Ziyang Zhong, Chief Executive Officer of Anwita. “We are excited to share at SITC 2022 additional preclinical data demonstrating the potential of anti-PD-1-IL-2 to drive targeted and safer antitumor immune responses, and to present new data on the preclinical development of an anti-LAG-3-IL-2 fusion protein as well as a no-alpha selective agonist of beta/gamma-IL-2R.”

Details for the abstract and poster presentation are as follows:

Abstract Number: 1104
Title: A safe and highly potent PD-1-IL-2 fusion (AWT020) that decouples the efficacy and toxicity of IL-2 therapy
Session Date and Time: 11/10/2022 - 11/11/2022, 9:00 am – 8:30 pm

Abstract Number: 1088
Title: A highly potent anti-LAG-3-IL-2c that selectively targets tumor-specific CD8+ T cells
Session Date and Time: 11/10/2022 - 11/11/2022, 9:00 am – 8:30 pm

Abstract Number: 1081
Title: Exenokine-2: a half-life extended no-α-IL-2 with improved preclinical pharmacological properties supports first-in-human clinical development
Session Date and Time: 11/10/2022 - 11/11/2022, 9:00 am – 8:30 pm

About Anwita Biosciences, Inc.
Anwita Biosciences, Inc. is an emerging biopharmaceutical company headquartered in the San Francisco Bay Area. Our mission is to deliver transformative treatment options to improve the lives of patients with cancer and autoimmune diseases. Anwita specializes in the discovery and development of optimized immunotherapeutics, leveraging its core expertise in cancer immunotherapy, bioinformatics, and structure-based protein engineering.
Investor Relations
Contact: Investor Relations
Telephone: (650) 600-9828
Email: contact@anwitabio.com
Website: www.anwitabio.com